- By Ambry Genetics
- Posted August 4, 2020
Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Breast Cancer
Ambry Genetics and the Mayo Clinic recently collaborated on the publication of “The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer from a Clinical Genetic Testing Cohort” in JNCI: The Journal of the National Cancer Institute (April 2020). Interested in hearing about the study from one…
- By Deepti Babu, MS, CGC
- Posted April 14, 2017
Ambry Genetics and Leading Academic Researchers Collaborate to Improve Knowledge of Genetic Risk Factors for Breast Cancer
New clinical evidence collected from >65,000 women with breast cancer demonstrates 83% of positive test results are found in genes that impact clinical management Multi-gene germline genetic testing allows for efficient analysis, maximizing risk assessment while minimizing the time needed for results. This has been particularly effective…
- By Deepti Babu, MS, CGC
- Posted December 23, 2016
New Research on Male Breast Cancer: Unexpected Results and Insights
Breast cancer in men may be rare in the average population, but is far more common in people with an underlying genetic predisposition. Finding a cancer gene mutation in a man with breast cancer can drastically impact medical management for him and his family members (who may otherwise not be screened for the disease). Current guidelines recommend…
- By Jackie Connor
- Posted December 14, 2016
Dr. Fergus Couch Talks with Ambry about Recent Study Findings
At Ambry we had the exciting opportunity to talk with Dr. Fergus Couch, Mayo Clinic Researcher, about his involvement with our Mayo Clinic research collaboration. “Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients,” which was the largest hereditary…